COMMUNIQUÉS West-GlobeNewswire

-
ZIVO Bioscience and Tianjin Norland Biotech Execute Letter of Intent to Produce ZIVO Algae Strain in China for International and Domestic Markets
01/02/2018 -
Making Breast Cancer Surgery Easier for Women: Over 25,000 Women in U.S. Experienced Wire-free Breast Tumor Localization with SAVI SCOUT®
01/02/2018 -
New Clinical Program at Amedisys for Heart Failure Patients Significantly Lowers Risks of Hospitalizations and Readmissions
01/02/2018 -
Progressive Care CEO, S. Parikh Mars Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
01/02/2018 -
Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product
01/02/2018 -
Emerald Health Therapeutics Achieves Tier 1 Listing on TSX Venture Exchange
01/02/2018 -
Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
01/02/2018 -
Nabriva Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
01/02/2018 -
Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
01/02/2018 -
AxoGen, Inc. to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
01/02/2018 -
RedHill Biopharma to Present at BIO CEO & Investor Conference
01/02/2018 -
Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis
01/02/2018 -
Coloplast delivers solid Q1 interim results and continues to take market share
01/02/2018 -
Announcement no. 02/2018 - Q1 Interim Financial Report, 2017/18
01/02/2018 -
Digirad Corporation Announces Quarterly Dividend of $0.055 Per Share
01/02/2018 -
JOBST Ranked #1 Physician Recommended Compression Therapy Brand in US
01/02/2018 -
BIOLIFE4D Launches Regulation A+ (Mini-IPO) Offering; Plans to Raise $50M
01/02/2018 -
Targovax ASA issues options to employees
01/02/2018 -
Saniona AB: Saniona's Partner, Medix, Completes Recruitment of Phase 3 Obesity Study of Tesofensine in Mexico
01/02/2018
Pages